Best of the IN VIVO Blog (10/2008)
This article was originally published in Start Up
In Vivo's bloggers rant about Bayer and its acquisition of Direvo; group hugs at the annual conference of Private Equity Analysts in New York; and the complete and utter destruction of Wall Street.
You may also be interested in...
Discussion at FDC/Windhover's annual Pharmaceutical Strategic Alliances gathering in New York reflected the urgent need for the industry to adopt new models in order to spur innovation--in R&D, finance, business development, and commercial operations.
In a still-frozen IPO market, acquisition has become the go-to exit for biotech VCs, but an analysis of the past four years' deals suggests the market may have peaked. Of more than 180 private biotech acquisitions since 2005, fewer than half in each year resulted in a reliable exit for investors, and those numbers are trending downward. Although the most active acquirers amounted to a list of the usual suspects, the bulk of acquisitions were conducted by a diverse set of smaller public and still-private firms. We also review the characteristics of those companies that have had success in terms of good exits for investors.
The spate of recent carve-outs from Boston Scientific has private equity and venture capital investors hungry for similar deals across the industry. But device companies don't seem to be serving much up.